Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.400
-0.050 (-2.04%)
Apr 28, 2026, 4:00 PM EDT - Market closed
CNTB Revenue
In the year 2025, Connect Biopharma Holdings had annual revenue of $64.00K, down -99.75%.
Revenue (ttm)
$64.00K
Revenue Growth
-99.75%
P/S Ratio
2,119.55
Revenue / Employee
$1,000
Employees
64
Market Cap
135.65M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 114.20M |
| Innate Pharma | 10.57M |
| Alpha Cognition | 10.22M |
| Equillium | 4.39M |
| Kazia Therapeutics | 1.27M |
| Spruce Biosciences | 697.00K |
CNTB News
- 5 days ago - Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis - GlobeNewsWire
- 4 weeks ago - Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Connect Biopharma Holdings Transcript: Study result - Transcripts
- 4 weeks ago - Connect Biopharma Announces $20.2 Million Private Placement Financing - GlobeNewsWire
- 4 weeks ago - Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study - GlobeNewsWire
- 4 weeks ago - Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD - GlobeNewsWire
- 7 weeks ago - Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 7 weeks ago - Connect Biopharma Holdings Transcript: Leerink Global Healthcare Conference 2026 - Transcripts